Home › Atrial Fibrillation › NCT05366361
The Dynamics of Human Atrial Fibrillation
Who can join
Ages 22 to 80 · All sexes
Full eligibility criteria
Inclusion Criteria: * referred for ablation or Maze surgery at Stanford Medicine for persistent AF (i.e. which requires cardioversion to terminate and/or lasts \>7 days) * Per our clinical practice and guidelines (Calkins et al., Heart Rhythm 2018), patients will have failed or be intolerant of \>or= 1 anti-arrhythmic drug. Patients after Maze surgery typically have failed prior endocardial ablation. Exclusion Criteria: * active coronary ischemia or decompensated heart failure * atrial or ventricular clot on trans-esophageal echocardiography * pregnancy (to minimize fluoroscopic exposure) * inability or unwillingness to provide informed consent * rheumatic valve disease (results in a unique AF phenotype) * thrombotic disease or venous filters * prior chest surgery is a relative contraindication for Maze surgery
About the study
Atrial fibrillation (AF) is an enormous public health problem in the United States, affecting 2-5 million Americans and causing rapid heart beats, stroke, heart failure or death. In this project, the applicant will develop a novel framework to better understand human AF that builds on agreement between several concepts for the disease. The applicant will develop strategies to identify AF patients who will best respond to each of several therapies, to guide personalized therapy.
Sponsor: Stanford University · Participants: 200 · Started: Aug 18, 2020
Contact the study team
- Anson Lee, MD · Phone: (650) 724-7500
Official record on ClinicalTrials.gov — NCT05366361
Locations in the U.S.
| California | Stanford University, Stanford |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.